|
Article Excerpt
On May 10, the FDA held an emergency meeting of its Oncologic Drugs Advisory Committee to discuss the anemia drugs that supposedly help people cope with chemotherapy. But several recent studies were halted prematurely because these drugs--Epogen, Procrit, Aranesp--caused an increased death rate, cancer progression, deep-vein blood clots and heart damage (see last month's newsletter). Ultimately, the FDA advisory committee asked for better studies and voted to put more stringent warnings on the labels for these drugs, known collectively as EPO. Unfortunately, few doctors ever read...
|
|
More articles from HealthFacts
Cancer patients on chemotherapy are surveyed about use of all other dr..., June 01, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
